GB0425077D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0425077D0
GB0425077D0 GB0425077A GB0425077A GB0425077D0 GB 0425077 D0 GB0425077 D0 GB 0425077D0 GB 0425077 A GB0425077 A GB 0425077A GB 0425077 A GB0425077 A GB 0425077A GB 0425077 D0 GB0425077 D0 GB 0425077D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0425077A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to GB0425077A priority Critical patent/GB0425077D0/en
Publication of GB0425077D0 publication Critical patent/GB0425077D0/en
Priority to JP2007540606A priority patent/JP2008519800A/en
Priority to PCT/EP2005/012207 priority patent/WO2006050991A1/en
Priority to EP05802078A priority patent/EP1809606A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
GB0425077A 2004-11-12 2004-11-12 Novel compounds Ceased GB0425077D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB0425077A GB0425077D0 (en) 2004-11-12 2004-11-12 Novel compounds
JP2007540606A JP2008519800A (en) 2004-11-12 2005-11-10 Compounds having activity at the NK3 receptor and their use in medicine
PCT/EP2005/012207 WO2006050991A1 (en) 2004-11-12 2005-11-10 Compounds having activity at nk3 receptor and uses thereof in medicine
EP05802078A EP1809606A1 (en) 2004-11-12 2005-11-10 Compounds having activity at nk3 receptor and uses thereof in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0425077A GB0425077D0 (en) 2004-11-12 2004-11-12 Novel compounds

Publications (1)

Publication Number Publication Date
GB0425077D0 true GB0425077D0 (en) 2004-12-15

Family

ID=33523672

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0425077A Ceased GB0425077D0 (en) 2004-11-12 2004-11-12 Novel compounds

Country Status (4)

Country Link
EP (1) EP1809606A1 (en)
JP (1) JP2008519800A (en)
GB (1) GB0425077D0 (en)
WO (1) WO2006050991A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057130A1 (en) 2005-09-21 2007-11-14 Astrazeneca Ab ALKYL SULFOXIDE QUINOLINS AND A PHARMACEUTICAL COMPOSITION
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
US20080221161A1 (en) * 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
MX2010013868A (en) 2008-06-23 2011-02-24 Lundbeck & Co As H Isoquinolinone derivatives as nk3 antagonists.
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EA201170585A1 (en) 2008-10-20 2011-12-30 Х. Лундбекк А/С IZOHINOLINON DERIVATIVES AS ANTAGONISTS NK3
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EP3160469B1 (en) 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
EP3704271A4 (en) 2017-11-02 2021-09-08 California Institute of Technology Neurokinin antagonists and uses thereof
CN108752273A (en) * 2018-08-17 2018-11-06 湖北欣瑞康医药科技有限公司 A kind of preparation method of Cinchonic Acid's derivative of 3- straight chained alkyls carboxyl substitution

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316571B1 (en) * 1994-05-27 2002-05-30 파올로 비지, 엔리꼬 카쭐라니 Quinoline derivatives as tachykinin NK3 receptor antagonists
AP9801237A0 (en) * 1995-11-24 1998-06-30 Smithkline Beecham Farm S P A Quinoline derivatives.
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
EP0983262B1 (en) * 1997-05-23 2003-07-09 GlaxoSmithKline S.p.A. Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists

Also Published As

Publication number Publication date
JP2008519800A (en) 2008-06-12
EP1809606A1 (en) 2007-07-25
WO2006050991A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
EP1718638A4 (en) Novel compounds
GB0400812D0 (en) Novel compounds
GB0409744D0 (en) Novel compounds
GB0405628D0 (en) Novel compounds
GB0402140D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
EP1805132A4 (en) Novel compounds
EP1796793A4 (en) Novel compounds
GB0402357D0 (en) Novel compounds
GB0408083D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
GB0402355D0 (en) Novel compounds
GB0425075D0 (en) Novel compounds
GB0402356D0 (en) Novel compounds
GB0404105D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0402114D0 (en) Novel compounds
GB0406027D0 (en) Novel compounds
GB0402145D0 (en) Novel compounds
GB0402142D0 (en) Novel compounds
GB0402134D0 (en) Novel compounds
GB0402115D0 (en) Novel compounds
GB0407519D0 (en) Novel compounds
GB0402110D0 (en) Novel compounds
GB0401727D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)